BioGenerator Ventures creates, builds, and invests in companies that are solving important problems in human health and agriculture.

BioGenerator Ventures

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Florence Kurth

Florenz Sartorius

Sartorius Aktiengesellschaft

BioGenerator Ventures creates, builds, and invests in companies that are solving important problems in healthcare and agriculture.

May 14-16, BioGenerator will co-host a 5-part workshop covering all aspects of writing and submitting an SBIR/STTR proposal to the National Institutes of Health (NIH). 

The first webinar will cover which federal agencies participate, how funds can be used, etc. The next 4 workshops will go over each section of your proposal, including Specific Aims, Research Strategy, Human Subject Research, and more. 

We'll also look at NIH’s commercialization plan, including the value of your project and IP protection. Learn more and register today:https://bit.ly/4dxCYug

BioGenerator Ventures is delighted to announce a recent equity investment in St. Louis-based INTENT, an ag industry pioneer. The investment is intended to help accelerate INTENT’s industry-changing advancements in agriculture, with particular emphasis on INvision Trials software. 

This new software offers a completely redesigned interface for project management, presenting a geospatial visualization of all aspects of a field project in a scalable system that delivers quality data and powerful insights, with speed and agility.

“BioGenerator Ventures is excited to be part of INTENT and sees great value in the insights the company’s technology provides to both innovators and farmers,” said Matt Helms, Managing Director of BioGenerator Ventures, who joined the INTENT board of directors. “INTENT helps translate innovative new technologies to the real-world challenges that farmers must overcome.”

Read more: https://bit.ly/3PJsdvj

Ready to learn key information about SBIR/STTR funding – and gain insights into how to craft a competitive proposal that meets the unique requirements of the National Institutes of Health? Be sure to sign up for the *free* webinar series hosted by BioGenerator and BBC Entrepreneurial Training & Consulting. The sessions run September 19-21 and the registration link is here: https://bit.ly/3Pgqg8a

Now hiring: BioGenerator Ventures is looking for a talented and ambitious Healthcare Executive in Residence to assist BioGenerator’s team in building promising new St. Louis companies, and to help BioGenerator Ventures’ portfolio of more than 50 active companies. 

Through its Executive in Residence (EIR) program, BioGenerator supports a group of experienced business leaders to help build the next generation of St. Louis technology companies. 

Learn more and apply: https://bit.ly/3XU3OW8

Have you registered? Beginning 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄, BioGenerator will co-host a 5-part workshop covering all aspects of writing and submitting an SBIR/STTR proposal to the National Institutes of Health (NIH). 

The sessions run from May 14 to May 16 and will give participants a leg up in this competitive process. The first webinar will cover which federal agencies participate, how funds can be used, and other key fundamentals. 

The next 4 workshops will go over each section of your proposal, including Specific Aims, Research Strategy, Human Subject Research and more. We'll also look at NIH’s commercialization plan, including the value of your project and IP protection. Register now! https://bit.ly/49RiUA0

By helping startups secure financing and develop plans to scale up, BioGenerator Ventures gives new companies the solid footing they need to succeed long-term in St. Louis. Having that foundation is vital for supporting tech job opportunities, which have dropped precipitously over the past year, according to a recent report.

Listen to this story from St. Louis Public Radio to learn more about BioGenerator's important role in the St. Louis startup landscape.

Metric
Company Name	BioGenerator Ventures	Sartorius Aktiengesellschaft
Symbol		SRT
MSH ID	COM:BIOGENERATORVENTURES	COM:SARTORIUS
Market	PRIVATE	STOCKS
Sector	Financial Services & Finance	Healthcare
Industry	Venture Capital	Medical - Instruments & Supplies
Country	US	DE
Stage
Employee Count	36	14.61K
Website	biogeneratorventures.com	sartorius.com
LinkedIn	biogeneratorventures	sartorius
Founders

Metric
Market Cap		15.56B
Enterprise Value
Monthly Web Traffic	1.21K	1.07M
Web Traffic Growth	-0.18	1.47
Valuation
Raised Capital

Metric
Revenue		3.59B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.66B
EBITDA		890.51M
Operating Income		528.96M
Net Income		357.53M
EPS		5.23
Diluted EPS		5.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.46
Operating Profit Margin		0.16
EBITDA Margin		0.25
Net Profit Margin		0.09
Return on Equity		0.15
Return on Assets		0.03
Return on Capital Employed		0.07

BIOG

COM:BIOGENERATORVENTURES

BioGenerator Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		41.01
P/B Ratio		8.67
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		6.48
EV Multiple		19.08

Metric
Days Sales Outstanding		42.10
Days Payables Outstanding		91.49
Days Inventory Outstanding		206.95
Operating Cycle		260.52
Cash Conversion Cycle		181.83
Asset Turnover		0.35

Metric
Operating Cash Flow		901.60M
Free Cash Flow		310.43M
Cash Flow to Debt		0.18
Operating Cash Flow/Sales		0.25
Free Cash Flow Yield		0.01

Metric
Cash & Equivalents		400.52M
Accounts Receivable		178.08M
Inventory		1.10B
Goodwill		3.61B
Debt to Capitalization		0.72
Debt to Assets		0.54
Current Ratio		1.49
Quick Ratio		1.19

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.05
SG&A to Revenue		0.05